Despite quarterly revenue totals that were nearly cut in half compared to the same period last year, Moderna still expects to ...
Reports third quarter revenue of $1.0 billion, GAAP net loss of $(0.2) billion and GAAP EPS of $(0.51) Narrows 2025 projected ...
Moderna (($MRNA)) has held its Q3 earnings call. Read on for the main highlights of the call. During Moderna’s recent earnings call, the sentiment ...
Moderna posts a smaller Q3 loss, trims 2025 sales forecast, cuts R&D costs, and boosts cash outlook as COVID vaccine demand ...
Moderna Inc. shares rose after the company posted a narrower third-quarter loss than Wall Street expected, a sign that its ...
Moderna is suing Pfizer and BioNTech for infringing patents central to Moderna's mRNA technology platform used to develop the COVID vaccine, the company said in a press release Friday. A widely ...
Q3 2025 Earnings Call Transcript November 6, 2025 Moderna, Inc. beats earnings expectations. Reported EPS is $-0.51282, ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback